Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Recruiting 2Active not recruiting 2

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 26Genitourinary 4Head & Neck 3Gynecologic 2

Conditions

Urinary Bladder Neoplasms 4

Interventions

Magnetic Resonance Spectroscopy 101Specimen Handling 82pembrolizumab 78enzalutamide 63Nivolumab 60Gemcitabine 54Docetaxel 52apalutamide 42Radiosurgery 41Abiraterone Acetate 40Prednisone 39Androgen Antagonists 39Biopsy 37darolutamide 36Cisplatin 35cabozantinib 33Radiotherapy 32Carboplatin 29Pluvicto 28enfortumab vedotin 27abiraterone 27Ipilimumab 25Radiation 23durvalumab 22atezolizumab 22Leuprolide 20olaparib 19X-Rays 19Standard of Care 18avelumab 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
dehydroftorafur × Genitourinary × 90 days × Clear all
NCT06770582 2026-06-11

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
160 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT03775265 2026-05-29

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
475 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT04216290 2026-05-22

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
11 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT07097142 2026-05-04

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

NRG Oncology

Phase 3 Recruiting
486 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡